After a long silence, Wang Sicong landed on the hot search list again. On April 14, he forwarded a message about Lianhua Qingwen Capsule on his microblog, accompanied by words such as "CSRC should strictly investigate Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) ", which immediately aroused the attention of public opinion.
Subsequently, the Securities Department of Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) ( Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) . SZ) responded on this matter, "you can't ask questions at will because of the word 'Wang Sicong'. Just listen to some comments on the Internet. Investors please screen them."
The reporter of times weekly found that Wang Sicong edited again one hour after the release of the aforementioned microblog. The original remarks have been deleted, but they can still be seen in the editing records.
On the afternoon of April 14, the reporter of times weekly called the director of Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) securities department and brand center for many times, but the phone could not be connected as of the time of publication.
Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) was founded in 1992 and registered in Shijiazhuang, Hebei Province. Its main business is the R & D, production and sales of traditional Chinese medicine. The company has a GMP certified production line of capsules, tablets, granules and injections, as well as a chemical preparation workshop certified by the European Union.
Lianhua Qingwen was developed by a team led by Academician Wu Yiling in 2003. At that time, Wu Yiling developed the prescription of Lianhua Qingwen according to a large number of ancient prescriptions, but it was not allowed to produce and market until May 2004. Lianhua Qingwen is mainly used for the treatment of cold and influenza related diseases. It has been listed in the drug recommendation of diagnosis and treatment schemes related to respiratory diseases such as influenza A, influenza B and avian influenza for many times.
Since the outbreak of covid-19 epidemic in 2020, Lianhua Qingwen has been continuously included in the covid-19 diagnosis and treatment plan from the fourth edition to the ninth edition, and is recommended for observation, light and ordinary covid-19 patients. In March 18th, the National Health Protection Committee issued the "New Coronavirus pneumonia diagnosis and treatment plan (trial version ninth)".
At present, Lianhua Qingwen has been approved and sold in more than 20 countries and regions. When the overseas epidemic was serious, Lianhua Qingwen capsule was even "hard to find one drug", and the price was fried to a box of up to 300 yuan.
According to the data, in 2020, the sales revenue of Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) Lianhua Qingwen products reached 4.256 billion yuan, a year-on-year increase of 149.89%, accounting for almost half of the company's revenue.
Founder Wu Yiling's wealth has also risen. According to the 2020 Hurun global rich list, 71 year old Wu Yiling ranked 251th with a wealth of 21 billion yuan, ranking the richest man in Shijiazhuang.
In the first three quarters of 2021, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) revenue was 8.112 billion yuan and net profit was 1.224 billion yuan, which exceeded that of the whole year of 2020.
On April 14, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) rose the limit to close at 39.99 yuan / share, with a total market value of 66.812 billion yuan.
